Torrent Pharmaceuticals Ltd. Q2 FY2025 results: revenue ₹2,889 crore, up 8.6% on the year
Torrent Pharmaceuticals Ltd. (TORNTPHARM) reported consolidated revenue from operations of ₹2,889 crore for Q2 FY2025, the quarter ended 30 September 2024, up 8.6% on the same quarter a year earlier. Profit after tax was ₹453 crore, up 17.4% on the year, and earnings per share ₹13.37. The figures are the company's own, from the unaudited results it filed with NSE on 25 October 2024.
The quarter, against the one before and a year earlier
| Line | Q2 FY2025 | Q1 FY2025 | Q2 FY2024 | Change on the year |
|---|---|---|---|---|
| Revenue from operations | 2,889 | 2,859 | 2,660 | +8.6% |
| Other income | -16 | 24 | 26 | n/a |
| Total income | 2,873 | 2,883 | 2,686 | +7.0% |
| Cost of materials consumed | 337 | 411 | 433 | -22.2% |
| Purchases of stock-in-trade | 382 | 313 | 292 | +30.8% |
| Changes in inventories | -41 | -30 | -65 | n/a |
| Employee benefit expense | 543 | 550 | 503 | +8.0% |
| Finance costs | 64 | 75 | 91 | -29.7% |
| Depreciation, depletion and amortisation | 198 | 197 | 201 | -1.5% |
| Other expenses | 729 | 711 | 672 | +8.5% |
| Total expenses | 2,212 | 2,227 | 2,127 | +4.0% |
| Profit before exceptional items and tax | 661 | 656 | 559 | +18.2% |
| Exceptional items | 0 | 0 | 0 | n/a |
| Profit before tax | 661 | 656 | 559 | +18.2% |
| Current tax | 156 | 126 | 120 | +30.0% |
| Deferred tax | 52 | 73 | 53 | -1.9% |
| Total tax | 208 | 199 | 173 | +20.2% |
| Profit after tax | 453 | 457 | 386 | +17.4% |
| Attributable to owners of the parent | n/a | 457 | 363 | n/a |
| Other comprehensive income | -25 | -34 | -23 | n/a |
| Total comprehensive income | 428 | 423 | 363 | +17.9% |
| EPS, basic | ₹13.37 | ₹13.51 | ₹11.39 | +17.4% |
| EPS, diluted | ₹13.37 | ₹13.51 | ₹11.39 | +17.4% |
₹ crore except per share.
Quarterly results, the last 12 quarters
| Q2 FY2024 | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,660 | 2,732 | 2,745 | 2,859 | 2,889 | 2,809 | 2,959 | 3,178 | 3,302 | 3,303 | 4,197 | 4,921 |
| Expenses | 2,127 | 2,156 | 2,145 | 2,227 | 2,212 | 2,151 | 2,252 | 2,403 | 2,471 | 2,466 | 3,585 | 4,155 |
| Operating profit | 825 | 869 | 883 | 904 | 939 | 914 | 964 | 1,032 | 1,083 | 1,088 | 1,356 | 1,664 |
| OPM % | 31% | 32% | 32% | 32% | 33% | 33% | 33% | 32% | 33% | 33% | 32% | 34% |
| Other income | 26 | -33 | 31 | 24 | -16 | 33 | -18 | -37 | -27 | -13 | -17 | -12 |
| Interest | 91 | 80 | 80 | 75 | 64 | 57 | 56 | 56 | 48 | 45 | 236 | 305 |
| Depreciation | 201 | 213 | 203 | 197 | 198 | 199 | 201 | 201 | 204 | 206 | 508 | 593 |
| Exceptional items | 0 | 88 | 0 | 0 | 0 | 0 | -24 | 0 | -13 | -10 | -66 | -21 |
| Profit before tax | 559 | 631 | 631 | 656 | 661 | 691 | 665 | 738 | 791 | 814 | 529 | 733 |
| Tax % | 31% | 30% | 29% | 30% | 31% | 27% | 25% | 26% | 25% | 22% | 31% | 23% |
| Net profit | 386 | 443 | 449 | 457 | 453 | 503 | 498 | 548 | 591 | 635 | 364 | 566 |
| EPS in ₹ | ₹11.39 | ₹13.10 | ₹13.27 | ₹13.51 | ₹13.37 | ₹14.88 | ₹14.71 | ₹16.19 | ₹17.45 | ₹18.77 | ₹11.51 | ₹14.87 |
| Filing | NSE | NSE | NSE | NSE | NSE | NSE | Filing | Filing | Filing | Filing | Filing | Filing |
₹ crore except per share, consolidated, as filed with the exchange. Operating profit is sales less the expenses other than interest and depreciation, OPM is that over sales, and tax % is tax over profit before tax: arithmetic on the filed lines; everything else is as filed. Quarters before December 2024 are from the exchange's earlier results feed, which carries the filed lines without the filing itself; the column links to the exchange's page for the company.
Source
Unaudited consolidated results for the quarter ended 30 September 2024, filed with NSE on 25 October 2024: the result statement. All of Torrent Pharmaceuticals Ltd.'s results: NSE company page.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.